A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

Conditions

• Chronic Obstructive Pulmonary Disease With Chronic Bronchitis

Eligibility Criteria

Sex

ALL

Age

40 Years - 80 Years

Healthy Volunteers

Not accepted

Interventions

• Galvokimig — BIOLOGICAL
  Drug: Galvokimig Pharmaceutical form: Solution for injection
• Placebo — BIOLOGICAL
  Drug: Placebo Pharmaceutical form: Solution for injection

Study Details

The purpose of the study is to investigate the efficacy of galvokimig versus placebo in the time to the first acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in study participants with moderate-to-severe COPD with chronic bronchitis.

Key Dates

First listed

Jul 24, 2026

Start date

Jul 27, 2026

Status verified

Jul 2026

Primary completion

Jun 29, 2029

Completion

Jun 29, 2029

Study Design

Enrollment

402 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Galvokimig Dose 1 Arm
  Participants randomly assigned to this arm will receive a predefined Galvokimig Dose.
• Experimental: Galvokimig Dose 2 Arm
  Participants randomly assigned to this arm will receive a predefined Galvokimig Dose.
• Placebo Comparator: Placebo Arm
  Participants randomly assigned to this arm will receive a matching Placebo.

Primary Outcome Measure

Time from treatment assignment to first moderate or severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD) [ Time Frame: Up to Week 60 ]

Central Contacts

• UCB Cares
  1-844-599-2273 (USA)
  [email protected]
• UCB Care
  0018445992273
  [email protected]

Locations (1)

Find similar trials in Boerne, TX